Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
N-glycosylation in the SERPIN domain of the C1-esterase inhibitor in hereditary angioedema
Zhen Ren, John Bao, Shuangxia Zhao, Nicola Pozzi, H. James Wedner, John P. Atkinson
Zhen Ren, John Bao, Shuangxia Zhao, Nicola Pozzi, H. James Wedner, John P. Atkinson
View: Text | PDF
Research Article Immunology

N-glycosylation in the SERPIN domain of the C1-esterase inhibitor in hereditary angioedema

  • Text
  • PDF
Abstract

Hereditary angioedema is an autosomal dominant disorder caused by defects in C1-esterase inhibitor (C1-INH), resulting in poorly controlled activation of the kallikrein-kinin system and bradykinin overproduction. C1-INH is a heavily glycosylated protein in the serine protease inhibitor (SERPIN) family, yet the role of these glycosylation sites remains unclear. To elucidate the functional impact of N-glycosylation in the SERPIN domain of C1-INH, we engineered 4 sets consisting of 26 variants at or near the N-linked sequon (NXS/T). Among these, 6 are reported in patients with hereditary angioedema and 5 are known C1-INH variants without accessible clinical histories. We systematically evaluated their expression, structure, and functional activity with C1s̄, FXIIa, and kallikrein. Our findings showed that of the 11 reported variants, 7 were deleterious. Deleting N at the 3 naturally occurring N-linked sequons (N238, N253, and N352) resulted in pathologic consequences. Altering these sites by substituting N with A disrupted N-linked sugar attachment, but preserved protein expression and function. Furthermore, an additional N-linked sugar generated at N272 impaired C1-INH function. These findings highlight the importance of N-linked sequons in modulating the expression and function of C1-INH. Insights gained from identifying the pathological consequences of N-glycan variants should assist in defining more tailored therapy.

Authors

Zhen Ren, John Bao, Shuangxia Zhao, Nicola Pozzi, H. James Wedner, John P. Atkinson

×

Figure 2

Illustration of key domains in C1-INH.

Options: View larger image (or click on image) Download as PowerPoint
Illustration of key domains in C1-INH.
The reactive center loop (RCL) is...
The reactive center loop (RCL) is in pink. The regions involved in SERPIN function are labeled. The P15-P9 portion of the RCL, the hinge domain, is highly conserved and facilitates the insertion of RCL into β-sheet A (SA). The breach region lies on the top of SA, the initial insertion site of RCL. The shutter domain, composed of S3A and S5A, is in the center of SA and facilitates the RCL insertion. The gate region consists of strands 3 and 4 from β-sheet C (S3C and S4C). N-glycosylation sites are shown as blue spheres. The P1 and P′ are displayed as rainbow sticks and are responsible for trapping the target protease. Strands of central SA are in cyan. The 2 disulfide bridges are labeled and colored in red. Protein structures used for modeling were obtained from the PDB database (PDB: 5DU3). The figure was generated using Pymol (3.0) and serves as a model for structure analyses in Figures 4–7. NTD, amino-terminal domain; CTD, carboxyl-terminal domain.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts